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Abstract
OBJECTIVE: To evaluate systematically the clinical
efficacy and safety of Qingkailing (QKL) injection in
the treatment of acute stroke.
METHODS: Searches for randomized controlled
trials into acute stroke treated with QKL injection
were performed in the China National Knowledge
Infrastructure Database, China Science and
Technology Journal Database, Wan fang Database,
Chinese Biomedical Literature Database, PubMed
and Cochrane Library, from January 1979 to March
2013. Two reviewers independently retrieved the
RCTs and extracted the information. The Cochrane
risk of bias method was used to assess the quality
of the included studies, and a Meta-analysis was
conducted with Review Manager 5.2 software.
RESULTS: A total of 13 studies with 1110
participants were included. The quality of the
studies was generally low. The Meta-analysis
indicated that the combined use of QKL and
Western Medicine was significantly superior to
control group therapy in terms of the total effective
rate. The relative risk (RR) in the acute cerebral
hemorrhage (ACH) sub-group was 1.17 [95%
confidence interval (CI) (1.08, 1.26), P=0.0001]. In
the acute cerebral infarction (ACI) sub-group, RR
was 1.27 [95% CI (1.14, 1.42), P<0.0001], and in the
ACH and ACI mixed sub-group, RR was 1.34 [95% CI
(1.20,1.50),P<0.00001]. Additionally, QKL promoted
the absorption of hematoma [mean difference
(MD)=﹣3.73, 95%CI (﹣4.48, ﹣2.98), P<0.000 01],
decreased neurological damage in ACI [MD=
﹣5.60, 95% CI (﹣8.50,﹣2.70), P=0.0002] and ACH
[MD= ﹣ 4.08, 95% CI (﹣ 8.00, ﹣ 0.16), P=0.04],
promoted the recovery of awareness [RR=1.56, 95%
CI (1.09, 2.21), P=0.01] and reduced the whole
blood viscosity coefficient [MD=﹣ 0.75, 95% CI
(﹣ 1.47, ﹣ 0.03), P=0.04]. There were no adverse
drug reactions reported in the included studies.
CONCLUSION: Based on this systematic review,
QKL combined with conventional therapy was
effective compared with control treatment.
However, because the articles used in the study
were not of high quality, further studies should be
conducted into the efficacy and safety of QKL in
treating acute stroke.
© 2014 JTCM. All rights reserved.
Key words: Qingkailing injection; Stroke; Acute
cerebrovascular disease; Meta-analysis; Rando-
mized controlled trials; Review
131
JTCM |www. journaltcm. com April 15, 2014 |Volume 34 | Issue 2 |
Wu JR et al. / Systematic Review
INTRODUCTION
In Western Medicine (WM), acute stroke is also
known as acute cerebrovascular disease. It includes
acute cerebral infarction (ACI), acute cerebral
hemorrhage (ACH), cerebral embolism and
subarachnoid hemorrhage.1 Stroke can be divided into
two types: ischemic stroke and hemorrhagic stroke.
Ischemic stroke includes cerebral infarction and
cerebral thrombosis, and the most common case of
hemorrhagic stroke is cerebral apoplexy. Stroke has one
of the highest incidences of the cerebrovascular
diseases. It results in high rates of morbidity, mortality
and disability, and often contributes to sequelae that
may seriously threaten human health. The majority of
survivors (60%) require the help of medical institutions;
their lives may be dramatically affected and the
possibility of recurrence is high. At the same time,
stroke is one of the most expensive diseases to treat,
which can bring a great deal of economic burden to
patients.2-4 Results of some studies have shown that the
incidence of stroke is increasing. Therefore, methods to
treat acute stroke effectively and reduce the impact of
its sequelae have become foci for research.5
Qingkailing injection (QKL) is derived from
Angongniuhuang pills. Its main ingredients include
Niuhuang (Calculus Bovis), Shuiniujiao (Cornu
Bubali), Huangqin (Radix Scutellariae Baicalensis),
Jinyinhua (Flos Lonicerae), and Zhizi (Fructus
Gardeniae). It has a variety of functions: as an
antifebrile agent and hepato-protectant, in regulating
immunity, promoting the absorption of intracranial
hematoma and reducing cerebral edema.6 QKL is used
widely in the clinical setting in the areas of
cerebrovascular disease, acute infectious diseases,
pediatric diseases and otorhinolaryngologic diseases,
among others. It has achieved significant effects in the
treatment of stroke, hepatitis, and in cardiovascular
and pediatric diseases.7 Recently, more and more
clinical cases have been reported describing QKL as an
emergency treatment for acute stroke with fever.8 All of
these reports have shown that QKL could increase the
efficacy rate of emergency rescue in Traditional
Chinese Medicine (TCM).
Although there have been several previous
Meta-analyses regarding stroke,9-13 their focus has been
on either cerebral infarction or cerebral hemorrhage
only. Rather, this systematic review aims to evaluate
objectively the efficacy and safety of QKL in treating
acute stroke without classification, providing a
scientific basis for its clinical use in acute stroke, the
reason of no classification was QKL was efficacy in
both hemorrhagic and ischemic stroke that indicated
in one study.14
MATERIALS ANDMETHODS
Study search
Two reviewers retrieved randomized controlled trials
(RCTs) by searching the following databases from
January 1979 to March 2013: the China National
Knowledge Infrastructure Database, Wan fang
Database, China Science and Technology Journal
Database, Chinese Biomedical Literature database,
PubMed, and the Cochrane Library. The search terms
included "Qingkailing" as a MeSH term and then
"stroke or cerebrovascular diseases" for secondary
retrieval. Studies published in English or Chinese were
considered.
Inclusion criteria
Studies meeting the following criteria were included.
Clinical RCTs used QKL to treat acute stroke,
regardless of blinding. The diagnostic criterion in
terms of TCM was "apoplexy diagnostic efficacy
assessment standards"; that used in terms of WM was
"the various types of cerebrovascular disease diagnostic
points", as determined in 1995.15 Diagnoses were
validated using computer tomography or magnetic
resonance imaging scanning. The courses of disease
were 7 days or shorter; this is considered the acute
phase of stroke. All patients were experiencing the first
onset of stroke, and no limits were placed on age,
gender, race or severity of disease. The control group
was treated with predominantly two types of
conventional WM: patients with cerebral hemorrhage
received hemostatics, drugs lowering intracranial
pressure, anti-hypertensives and anti-infectives;
patients with cerebral infarction received vasodilators
and anti-hyperlipidemics. Both types of patients
required brain cell activators. The experimental group
was treated with WM on the same basis as the control
group, but combined with QKL. None of the therapies
was combined with any other Chinese medicine,
surgery or acupuncture. The dosages and treatment
courses were not limited. The primary outcome was
the total effective rate, using the following formula:
total effective rate=(number of recovered patients +
number of patients with significant progress + number
of patients with progress)/total number × 100% .
Efficacy criteria predominantly referred to a reduction
in the neurological deficit score, and to the living
ability of patients (or the degree of disability).
Recovery was determined when the functional deficit
score decreased by between 90% and 100% , and the
degree of disability was 0. Significant progress was
determined when the functional deficit score decreased
by between 46% and 89%, and the degree of disability
was 1. Progress was determined when the functional
deficit score decreased by between 18% and 45%. No
change or deterioration was determined when the
functional deficit score decreased by <18%.15 Secondary
outcomes were: the degree of absorption of cerebral
hematoma, the improvement of neurological deficits,
restoration of awareness (based on the duration of
patients' unconsciousness, and wake-up time),
hemorheology index, and the number of adverse drug
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reactions (ADR)/adverse drug events (ADE) identified.
The degree of absorption of the cerebral hematoma
was judged by hematoma size and the following
absorption rate calculation formula: V=1/2×L×S×the
slice, where L is the longest diameter of the largest
hematoma, S is the width, and the 'slice' is the layers
of lesion.16 The absorption rate of the hematoma=
(before treatment － after)/treatment before × 100% .
The judgment of the degree of neurological deficit
was based on the standard score of the degree of
neurological deficit of stroke, as determined in 1995:
light 0-15 points, medium 16-30 points and heavy
31-45 points. The evaluation of clinical efficacy=
(points before － after)/points before treatment ×
100%.16
Data extraction and quality assessment
For the included studies, two reviewers extracted the
data and screened them according to the inclusion
criteria. Any disagreements on data extraction and
study evaluation were resolved through discussion.
The extracted data included study type, patients'
characteristics, and information about treatment. We
assessed the risk of bias in the included trials strictly
according to the Cochrane risk of bias tool. This
addressed random sequence generation, allocation
concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete
outcome data, selective reporting, and other biases.
For each item, there were three grades of risk: low
risk of bias, unclear, and high risk of bias. When
inadequate information was presented in the article
and we were unable to explicitly judge "high" or
"low", the item was judged as "unclear". Two
researchers independently completed and mutually
checked the allocated grades. Any dispute was
resolved through discussion or with the assistance of
a third researcher.
Statistical analysis
The Revman 5.2 software package that produced and
updated by the Nordic Cochrane Centre was used to
analyze the collected data. Relative risk (RR) was used
for dichotomous data, and mean difference (MD) was
used for continuous variables, both with a 95%
confidence interval (95% CI), P<0.05 was considered
statistically significant between experimental and
control group. The Chi-square test was used for
checking the heterogeneity between studies, and I² was
used to show the size of heterogeneity. If P>0.1 and I²<
25% , there was determined to be little heterogeneity
between studies, then we used a fixed effect model,
otherwise we should use a random effect model. If the
number of included trials was sufficient, a funnel plot
would be carried out to assess publication bias. Because
we focused on stroke comprehensively in the study, the
comparison was split into three sub-groups: ACI, ACH
and a mixed sub-group. This took into account the
differences in therapy between the different sub-groups.
Sensitivity analysis was performed on "the total
effective rate" indicators, to indicate the stability of the
result.
RESULTS
Analysis of literature and assessment of quality
In this review, 484 articles were retrieved from the
databases listed above. After excluding duplications,
reviews and obviously irrelevant studies by reading the
titles and abstracts, 141 papers were downloaded for
further assessment. After reading the full texts, studies
that did not meet the inclusion criteria, non-RCTs,
studies in which there was a lack of information
regarding the control group, or individual clinical cases,
were excluded. A total of 13 studies were eventually
included,16-28 all published in Chinese Journal Literature
Databases from 1995 to 2011 (Figure 1).
Figure 1 Flow chart of literature search
CNKI: China National Knowledge Infrastructure Database; CBM: Chinese Biomedical Literature Database; VIP: Chinese Scientific
Journals Database; RCT: randomized controlled trial.
CNKI
(n=147)
Combining Chinese
medicine (n=52)
Lack the information of
control (n=58)
Duplicated=89
Irrelevant, animal study,
reviews (n=272)
Cochrane
(n=0)
CBM
(n=256)
VIP
(n=54)
Wanfang
(n=25)
PubMed
(n=2)
Total
(n=484)
Full text
(n=123)
RCT included
(n=13)
Excluded
Excluded
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Therefore, 1110 patients were included in the
systematic review. The QKL group consisted of 585
patients, while the control group consisted of 525
patients. All of the patients were undergoing their first
onset of stroke, and received treatment in hospital
within a week. The average age of the patients was
approximately 62.9 years, and all of the trials included
more males (60% ) than females. All of the inter-
ventions consisted of QKL combined with WM, and
the dosage of QKL was 30-80 mL every day. The
duration of treatment for both experimental and
control groups was not more than 28 days. More
details regarding the individual trials are presented in
Table 1.
Study
Zhang
S
201116
Wang
QF
201117
Guo
CE
200818
Li YQ
200519
Zeng
H
200320
Hou
B
200621
Zhang
YY
200322
Liang
SH
200023
Lv J
199824
Wang
AJ
200625
Liu Q
200426
Wang
Y
200027
Shou
XY
199528
Sex
(M/F)
34/26
40/16
70/62
55/35
36/28
53/27
46/24
47/33
54/14
64/56
56/64
43/25
68/34
AVG age
(extension)
58
(42-72)
55
(41-78)
66
(52-78)
67
(34-80)
(47-77)
63
63
(43-76)
61
67
(32-84)
69
(22-79)
64
(48-86)
62
(41-83)
60
Disease
diagnose
ACH
Avg of
bleeding=
19.02 mL
ACH
ACH
Avg of
bleeding
≤30 mL
ACH
ACI
ACI
ACI
ACI
ACI
ACI 66
ACH 54
ACI/
ACH
ACI 45
ACH 23
ACI 81
ACH 21
N
(Q/C)
30/30
28/28
66/66
45/45
34/30
40/40
40/30
40/40
38/30
60/60
60/60
34/34
70/32
Course
of
disease
(h)
24
24
144
48
24
48
72
72
72
72
168
48
72
Therapy
of
experiment
group
QKL
50 mL/q.d.
+WM
QKL
50 mL/q.d.
+WM
QKL
60 mL/q.d.
+WM
QKL
40 mL/q.d.
+WM
QKL
60 mL/q.d.
+WM
QKL
30 mL/q.d.
+WM
QKL
60 mL/q.d.
+WM
QKL
30 mL/q.d.
+WM
QKL 40-
60 mL/q.d.
+WM
QKL40-80
mL/q.d.
+WM
QKL
40 mL/q.d.
+WM
QKL
40mL/q.d.
+WM
QKL60-
80mL/q.d.
+WM
Therapy
of
control
WM
WM
WM
WM
WM
WM
WM
WM
WM
WM
WM
WM
WM
Treatment
(weeks)
14
20
28
28
20
15
28
28
28
15
15
7
28
Outcome
Total effective
rate, the
absorption of
hematoma,
the score of
neurological
deficit
Total effective
rate, the
absor- ption
of hematoma
Total effective
rate
Total effective
rate, the
absorption of
hematoma
Total effective
rate, the score
of neuro-
logical deficit
Total effective
rate, the score
of neuro-
logical deficit
Total effective
rate
Total effective
rate
Total effective
rate, blood
viscosity
Total effective
rate, blood
viscosity
Total effective
rate
Total effective
rate
Total effective
rate
ADR/
ADE
Unclear
Unclear
Unclear
None
Unclear
Unclear
Unclear
None
None
None
None
Unclear
Unclear
Table 1 Characteristics of 13 included studies on QKL for acute stroke
Notes: M: male; F: female; AVG: average; Q: QKL; C: control; ACH: acute cerebral hemorrhage; ACI: acute cerebral infarction; QKL:
Qingkailing injection; WM: conventional therapy with Western Medicines, including therapy for ACI with dextran 40, citicoline and
other drugs, and therapy for ACH with mannitol and other drugs; ADR: adverse drug reaction; ADE: adverse drug event.
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Study quality was evaluated by the Cochrane risk of
bias tool. All of the studies referred to randomization,
but did not describe the method of randomization and
blinding. Two studies appeared to have incomplete
outcome data (Figures 2 and 3).
Total effective rate
All the studies compared the total effective rate
between two groups. The analysis was divided into
three sub-groups, according to the classification of
stroke: ACH, ACI and the mixed sub-group
containing both ACI and ACH. There were four
studies16-19 in the ACH sub-group, five studies20-24 in
the ACI sub-group and four studies25-28 in the mixed
sub-group. Following the tests of heterogeneity, the
fixed effects model could be used for all three
sub-groups, for which the result of the test of
heterogeneity of the ACH sub-group was P=0.27,
I²=23%, the ACI sub-group was P=0.51, I²=0%, and
the mixed sub-group was P=0.83, I²=0%. Compared
with the control group, QKL combined with WM
was more effective in treating any type of stroke.
There was a statistically significant difference
between the two groups in all of the sub-groups. The
RR in the ACH sub-group was 1.17 [95% CI (1.08,
1.26), P=0.0001], in the ACI sub-group was 1.27
[95% CI (1.14, 1.42), P<0.0001] and in the mixed
sub-group was 1.34 [95% CI (1.20, 1.50), P<0.000 01]
(Figure 4). Because there was heterogeneity between
the three subgroups (P=0.11, I² =55.1>25%), we did
not merge the results.
Sensitivity analysis
To confirm the stability of the total effective rate
results, we removed the most and the least weighted of
every sub-group, and changed from fixed mode to
random mode. In the ACH sub-group, after removing
the most weighted (Guo et al 18), the result was RR=
1.17 [95% CI (1.01, 1.37), P=0.04]. The result of
removing the least weighted (Wang et al 17) was RR=
1.15 [95% CI (1.05, 1.24), P=0.001], and the result of
changing the mode was RR=1.15 [95% CI (1.05,
1.25), P=0.002]. Processing the other two groups in a
similar way, the results for the ACI sub-group were:
RR=1.26 [95% CI (1.10, 1.43), P=0.0005], RR=1.22
[95% CI (1.09, 1.36), P=0.0006] and RR=1.25 [95%
CI (1.12, 1.38), P<0.0001]. The results for the mixed
sub-group were: RR=1.36 [95% CI (1.18, 1.56), P<
0.0001], RR=1.32 [95% CI (1.18, 1.48), P=0.0002]
and RR=1.34 [95% CI (1.20, 1.49), P<0.000 01].
There was no clear difference compared with the
previous results, so the degree of sensitivity of the
study was not high.
Degree of absorption of cerebral hematoma
Two studies16,17 mentioned hematoma size and
absorption. Following the test for heterogeneity (P=
0.93>0.1, I² =0<25% ), we used a fixed model. The
Meta-analysis showed that QKL combined with WM
was better than WM alone in promoting the
absorption of hematoma. The statistical difference
between the two groups was significant [MD=﹣3.73,
95%CI (﹣4.48,﹣2.98), P<0.000 01] (Figure 5).
Figure 2 Risk of bias graph of included trials
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding (performance bias and detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
High risk of biasLow risk of bias Unclear risk of bias
0% 25% 50% 75% 100%
Figure 3 Summary of risk of bias
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding (performance bias and detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
GuoCE2008 18
HouB2006 21
LangSH
2000 23
LiuQ
2004 26
LiYQ
2005 19
LvJ1998 24
ShouXY1995 28
WangAJ2006 25
WangQF2011 17
WangY2000A
27
ZengH
2003 20
ZhangS2011 16
ZhangYY2003 22
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Figure 4 Meta-analysis of the total effective rate of QKL plusWM vsWM in treating acute stroke
QKL: Qingkailing injection;WM: conventional therapy withWestern Medicines.
Figure 5 Meta-analysis of the degree of absorption of cerebral hematoma using QKL plusWM vsWM in acute stroke
QKL: Qingkailing injection;WM: conventional therapy withWestern Medicines.
Figure 6 Meta-analysis of the improvement of neurological deficit using QKL plusWM vsWM in acute stroke
QKL: Qingkailing injection;WM: conventional therapy withWestern Medicines.
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Improvement of neurological deficit
Three studies16,20,21 mentioned the improvement of
neurological deficit scores. One study16 was in the
ACH sub-group, the compared result was MD=﹣4.08
[95% CI (﹣8.00, ﹣0.16), P=0.04]. There was little
difference between the two groups. The test for
heterogeneity of the ACI sub-group (P= 0.19>0.1, I² =
41>25% ) indicated that a random model should be
used. The Meta-analysis showed that combined with
WM, QKL was more effective in improving
neurological deficit. There was a statistically significant
difference between the two groups [MD=﹣5.60, 95%
CI (﹣8.50,﹣2.70), P=0.0002] (Figure 6).
Improvement of awareness
Only one study27 that in the sub-group of mixed
mentioned improvement of awareness. The
Meta-analysis showed that QKL could improve the
disturbance of consciousness, and the statistical
difference between the experimental and control group
was significant [RR=1.56, 95% CI (1.09, 2.21), P=
0.01].
Whole blood viscosity coefficient
Hyperviscosity can lead to slower blood flow, which
makes it easy for blood to form thrombose and cause
subsequent stroke. Two studies24,25 referred to the blood
viscosity coefficient, the results showing that QKL
could reduce the whole blood viscosity coefficient. The
result in the ACI group was statistically significantly
different [MD=﹣0.71, 95% CI (﹣0.87, ﹣0.55), P<
0.00001]; the result of the mixed ACI and ACH
sub-groups showed less statistically significant
difference [MD=﹣0.75, 95% CI (﹣1.47,﹣0.03), P=
0.04].
Safety
Only 5 studies19,23-26 mentioned clearly that there were
no ADRs reported in the included studies. While the
other 8 studies did not pay sufficient attention to the
safety aspects of QKL use, accordingly, we could not
conclude that QKL was absolutely safe.
DISCUSSION
Following the literature analysis, we concluded that
based on WM, QKL was effective when used for any
pattern of acute stroke. It could improve the total
effective rate, promote the absorption of brain
hematoma, decrease the degree of neurological deficit,
and reduce awareness restoration time and blood
viscosity. This could be expected to not only save
patients' lives, but also reduce the degree of sequelae
and recurrence of acute stroke. The result of this
Meta-analysis was supported by the findings of
previous research.9-13
In TCM, the basic pathogenesis of stroke is stagnation
of blood. In the acute phase of the disease, patients
may have inherent deficiency syndrome, while
externally, a positive syndrome may be present.29
During the acute phase of stroke in particular, the
positive syndrome is the main cause of pathogenesis
such as liver wind, heat evil, phlegm and blood stasis,
excess syndromes of the Fu-organs and aural
obstruction. Therefore, the treatment of stroke should
start with heat-clearing detoxification, blood stasis-
activating collaterals and awareness recovery. From the
perspective of pathology, ACH and ACI may result in
partial disorder of blood circulation, the formation of
cerebral edema,30 breaking the blood-brain barrier and
increasing free radicals. An animal experiment31 has
shown that the degree of brain damage was
significantly positively correlated with the increase of
free radicals. The prognosis of stroke has a very close
relationship with the effect of treatment in the acute
phase.29
Combining the opinions of TCM and Western
Medicine, the choice of medicine in the acute phase is
very important. QKL is derived from Angong-
niuhuang pills. Its main actions are heatclearing and
detoxifying, eliminating phlegm and freeing channels,
tranquilizing and allaying agitation, recovering
consciousness, and keeping the balance of Qi and
blood. QKL can also scavenge free radicals effectively,
which can reduce the occurrence of sequelae.31 Recent
research has indicated that QKL can also correct
metabolic disorders, improve cerebral circulation and
cerebral edema, and enhance brain cells' tolerance to
hypoxia. This can protect the brain cells, reduce infarct
size, and promote the absorption of hematoma.30
Based on the efficacy and pharmacological effects
described above, QKL may be the first choice for the
clinical treatment of acute stroke. Combining this with
the results of the Meta-analysis, we can conclude that
QKL combined with WM has a relatively good effect,
regardless of stroke disease-type.
Though there was no ADRs reported in the
Meta-analysis, the number of ADR reports regarding
QKL has gradually increased in clinical practice.32
From this, we may assume that the clinical use of QKL
for stroke may be relatively safe. Analyzing the ADR
reports from the clinical setting, the results show that
excessive dose is one of the reasons for QKL-related
anaphylactic shock. In addition, the occurrence of
ADRs may also be associated with the combining of
drugs. Therefore, medical staff should pay special
attention to controlling the dose, slowing down the
rate of infusion, and strictly abiding by the
requirement to avoid unnecessary drug combination,
in particular for drugs proven to be incompatible.33-34
In the clinical setting, as is emphasized in TCM, we
should discontinue the medication as soon as we gain
effect. It has been proven that 15 to 20 days is an
appropriate course of treatment when using QKL to
treat stroke.29 In summary, care should be taken to
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avoid the occurrence of ADRs when using QKL in the
clinical setting.
By analyzing the results of the ACI sub-group, the total
effective rate was RR=1.18<1.2. This means that QKL
used for ACI may not be ideal, although it showed a
statistically significant difference. Accordingly, further
studies are needed to evaluate QKL comprehensively,
for example, whether the economic burden of patients
will increase by using QKL, and whether using QKL
will alleviate the suffering of patients. The result of the
mixed sub-group warrants further research, as the total
effective rate was RR=1.34, which was greater than that
for the ACI or ACH sub-groups. This could perhaps
be related to the quality of the included studies.
Thirteen trials were included in the review, but they
were not large-scale RCTs, and none of them detailed
any random allocation or methods of blinding.
Further, all the included studies were published in
databases, and there was a lack of negative results,
which may have resulted in selection bias. More studies
with rigorously designed RCTs are therefore needed.
This systematic review showed that the combined use
of QKL with WM was effective. The combination may
increase the total effective rate, promote the absorption
of hematoma, improve the degree of neurological
damage and awareness, and decrease the whole blood
viscosity coefficient, which can improve efficacy for
treating acute stroke. Even though the safety of QKL
used for stroke requires further research, it is still one
of the first choices for the clinical treatment of stroke.
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